Apr. 13 at 6:24 PM
$SLS Checking my couch for loose change, because the math is officially undeniable.
Merck is losing
$30B/year, Eli Lilly has
$7.2B in fresh cash, and GSK is hunting Ovarian plays. Now look at the AACR data: SLS009 is literally stopping high-risk mutations in their tracks within 6 hours.
It works even against the "un-treatable" ASXL1 and TP53 mutations. It is doing things the medical world hasn't seen before. No toxicity. No chemo. Just results.
$MRK just valued a Phase 1 AML play at
$6.7 Billion. At that same valuation,
$SLS would be
$37.00/share.
$GILD paid
$5 Billion for a Phase 1 Ovarian play. That puts
$SLS at
$27.50/share.
$RVMD Revolution (
$26B) just proved that doubling survival =
$100+/share potential.
If you’ve got coins under the couch or in the pillows, plow them in now! Just awaiting the 80th event + Atomic Bombs 🚀 this weekend from SLS 009 .
Go back to sleep, we’ve already won.
